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Abstract Purpose: Thirty to forty
percent of patients with recurrent
gastrointestinal perforation/anasto-
motic leakage or acute necrotizing
pancreatitis develop intra-abdominal
invasive candidiasis (IC). A corrected
Candida colonization index (CCI)
C0.4 is a powerful predictor of IC.
Fluconazole prevents intra-abdominal
IC in this setting, but azole-resistant
Candida species are emerging. The
aim of this study was to explore the
efficacy and safety of caspofungin for
prevention of intra-abdominal IC in
high-risk surgical patients.
Methods: Prospective non-compar-
ative single-center study in
consecutive adult surgical patients
with recurrent gastrointestinal perfo-
ration/anastomotic leakage or acute
necrotizing pancreatitis. Preventive
caspofungin therapy (70 mg, then
50 mg/day) was given until resolution
of the surgical condition. Candida
colonization index and CCI, occur-
rence of intra-abdominal IC and
adverse events were monitored.
Results: Nineteen patients were
studied: 16 (84%) had recurrent gas-
trointestinal perforation/anastomotic
leakage and 3 (16%) acute necrotiz-
ing pancreatitis. The median duration
of preventive caspofungin therapy
was 16 days (range 4–46). The colo-
nization index decreased significantly
during study therapy, and the CCI
remained \0.4 in all patients. Ca-
spofungin was successful for
prevention of intra-abdominal IC in
18/19 patients (95%, 1 breakthrough
IC 5 days after inclusion). No drug-
related adverse event requiring ca-
spofungin discontinuation occurred.
Conclusion: Caspofungin may be
efficacious and safe for prevention of
intra-abdominal candidiasis in high-
risk surgical patients. This needs to be
further investigated in randomized
trials.
Keywords Caspofungin 
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Background
Invasive candidiasis (IC) has emerged as a frequent
complication in surgical critically ill patients [1, 2]. About
one-third of patients with recurrent gastrointestinal per-
forations, anastomotic leakages or acute necrotizing
pancreatitis develop intra-abdominal IC [3, 4]. Candida
colonization is a major risk factor for IC in this setting
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[5–7], and a corrected colonization index (CCI) C0.4
has been shown to predict IC with an efficiency of 100%
[8].
Early identification of non-neutropenic patients at high
risk of IC remains difficult and late therapy is associated
with high morbidity and mortality. Few data are available
on the utility of monitoring Candida colonization and/or
non-invasive fungal markers [9–13]. Clinical prediction
rules of the risk of IC have been investigated, but their
role for guiding the decision to start antifungal therapy
remains to be established [14, 15]. Fluconazole has been
shown to prevent IC in high-risk surgical patients with a
number needed to treat ranging between 3 and 10 [3, 12,
16–20]. In contrast, a study in ICU patients with persis-
tent fever despite antibacterial therapy (incidence of IC
9%) failed to demonstrate the efficacy of empirical
fluconazole therapy [21]. Based on a moderate to high
level of evidence, guidelines from the Infectious Diseases
Society of America (IDSA) recommend fluconazole
for prevention of IC in high-risk surgical ICU settings
[20, 22].
A broad use of azoles has been associated with a shift
towards infections due to non-albicans Candida species
with reduced antifungal susceptibility [23–26]. Preventive
antifungal therapy should thus be used very selectively in
patients at highest risk. Caspofungin, an approved agent
for therapy of mucosal and invasive candidiasis, is active
against azole-resistant Candida spp. [27]. As no experi-
ence on the role of echinocandins for prevention of intra-
abdominal candidiasis in high-risk surgical patients is
available, the aim of this study was to explore the efficacy
and safety of caspofungin in this setting.
Patients and methods
Design
We conducted a prospective non-comparative single-
center study between February 2006 and March 2007.
The study was approved by the institutional ethical
committee.
Patients’ selection
Inclusion criteria were: (1) age C16 years, (2) recurrent
gastrointestinal perforations/anastomotic leakage(s) after
abdominal surgery or surgery for acute necrotizing pan-
creatitis during the preceding 7 days, and (3) written
informed consent. Exclusion criteria were (1) documented
IC at study entry, (2) ongoing antifungal therapy during
[48 h, (3) severe hepatic insufficiency (Child–Pugh score
[9), (4) caspofungin allergy, (5) pregnant or lactating
woman, or (6) high probability of death within 72 h.
Preventive caspofungin therapy
A caspofungin loading dose (70 mg), was followed by
50 mg/day until resolution of the surgical condition
defined by (1) recovery of gastrointestinal function and
(2) no complication requiring surgical reintervention.
Clinical data
Demographic, clinical and laboratory data were collected
at study entry and then twice weekly until end of follow-
up, i.e., 1 week after end of study therapy or death.
Microbiological follow-up
Oral cavity, stool, urine, peritoneal fluid (at laparotomy or
from surgical drains), and additional sites according to
the underlying conditions were monitored for Candida
colonization. Candida cultures on Candida-specific chro-
mogenic plates (CAN2, Biomerieux, France) were
performed at study entry, twice during the first week, and
then once weekly until end of follow-up. Colonization was
assessed as weak, moderate, or heavy by semi-quantitative
cultures using the clock-streak technique [5]. The coloni-
zation index (number of sites colonized/number of sites
screened) and the CCI [(number of sites with heavy colo-
nization/number of sites colonized) 9 colonization index]
were calculated as previously reported [8]. Colonizing
species were differentiated as Candida albicans and non-
albicans.
Cultures of blood, urine, peritoneal fluid, surgical
wounds, and other sites were performed as clinically
indicated in the presence of symptoms/signs of infection.
Invasive Candida isolates were identified to the species
level and antifungal susceptibility was tested according to
CLSI standards [28].
Definitions of Candida infections
IC was defined by: (1) intra-abdominal candidiasis
including (1a) abscess with Candida isolated in pure or
mixed culture or (1b) peritonitis in presence of fever,
abdominal pain, tenderness on palpation, ileus, and leu-
kocytosis ([10 9 109/L) with isolation of Candida in the
peritoneal fluid from laparotomy or drain effluents (in
mixed bacterial and fungal cultures, Candida was regarded
as pathogen when recovered from blood or in increasing
amounts in serial cultures in absence of clinical improve-
ment despite appropriate surgical and antibacterial
treatment), (2) candidemia, i.e., positive blood cultures and
clinical symptoms/signs of infection, (3) Candida urinary
tract infection, i.e., [105 CFU/ml with pyuria and fever
without other focus and/or with local symptoms/signs of
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infection, (4) infection at another site, e.g., surgical wound
infection with Candida isolated from a biopsy specimen or
a purulent discharge.
Endpoints
The primary endpoint was the absence of breakthrough
intra-abdominal IC during and within 1 week after
discontinuation of preventive caspofungin therapy. Sec-
ondary endpoints were (1) absence of breakthrough extra-
abdominal IC, (2) survival, (3) Candida colonization
indices, and (4) drug-related adverse events according to
the National Cancer Institute criteria [29].
Statistics
No sample size calculation had been performed for this
observational non-comparative single-center exploratory
study. Continuous variables and proportions of Candida
colonization at start and end of preventive therapy were
compared by non-parametric paired Wilcoxon signed
rank test and Fisher’s exact test, respectively. The
correlation of continuous variables was studied by the
non-parametric Spearman rank test.
Results
Clinical characteristics
Nineteen patients were included in the study. Demo-
graphics and clinical characteristics are shown in Table 1.
All patients had abdominal surgery before inclusion:
explorative laparotomy with/without gut resection and/or
peritoneal lavage, or pancreatic necrosectomy. Fourteen
(74%) patients required additional abdominal surgery
after study entry.
Candida colonization
Data on Candida colonization are summarized in Table 2.
Colonization index and CCI at baseline and at end of
preventive caspofungin therapy are shown in Fig. 1. No
patient developed a CCI C0.4 during preventive therapy.
A decline of the colonization index was correlated with
the duration of preventive caspofungin therapy (Spearman
correlation coefficient r = -0.46, P = 0.049).
Success of preventive caspofungin therapy
Caspofungin was successful for prevention of intra-
abdominal IC in 18/19 patients (95%). Only one
breakthrough IC (mixed intra-abdominal abscess due to
Enterococcus spp., C. glabrata and C. lipolytica) occurred
in a patient with ischemic colitis and recurrent intestinal
perforations, who died from an intra-abdominal bleeding
5 days after study inclusion (no autopsy performed).
However, as no intra-abdominal sampling for culture was
available at baseline, an IC ongoing at study entry could not
be ruled out. At the time of diagnosis, the C. glabrata isolate
was susceptible to fluconazole and caspofungin (MIC 8 and
0.16 mg/l) and the C. lipolytica isolate had a reduced sus-
ceptibility to fluconazole (MIC 16 mg/l) and was
susceptible to caspofungin (MIC 0.25 mg/l). The patient
was colonized at study entry and remained colonized at
time of death by a non-albicans Candida spp. No extra-
abdominal breakthrough IC occurred.
Survival
Fourteen patients (74%) survived. Causes of death were:
(1) acute necrotizing pancreatitis with multiple organ
failure, intestinal perforation and bacterial peritonitis
(n = 2), (2) ischemic colitis with extended intestinal
necrosis, multiple perforations and bacterial peritonitis
(n = 2), and (3) intra-abdominal hemorrhage with con-
comitant breakthrough IC (n = 1, see above).
Table 1 Patients demographics and clinical characteristics
Patients 19
Gender: male/female 16/3
Age 69 (40–84)
Underlying surgical conditions
Gastrointestinal perforation/anastomotic leakage 16 (84%)
Necrotizing pancreatitis 3 (16%)
Number of abdominal surgical interventionsa
Before inclusion 2 (1–6)
During preventive caspofungin therapy 1 (0–6)
Antibiotic therapy at baseline 19 (100%)
Hospitalized in ICU 14 (74%)
APACHEb II score at ICU admission 17 (10–30)
SAPSc II score at ICU admission 45 (31–65)
Mechanical ventilation 10 (53%)
Days of ICU stay
Before inclusion 3 (0–14)
Overall 13 (3–56)
Days of preventive caspofungin therapy 16 (4–46)
Days of follow-up after study entry 28 (6–182)
Days of hospital stay
Before inclusion 10 (1–43)
Overalld 37 (17–194)
Data are median (range), unless specified otherwise
a Explorative laparotomy with/without gut resection and/or peri-
toneal lavage, or pancreatic necrosectomy for therapy of recurrent
gastrointestinal perforations/anastomotic leakage(s) or for acute
necrotizing pancreatitis
b Acute physiology and chronic health evaluation
c Simplified acute physiology score
d In 14 patients who survived and were discharged
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Adverse events (AE)
No AE with probable or proven relationship with caspo-
fungin was documented. AE possibly related to
caspofungin were observed in 8 patients (42%): chole-
stasis in 7 (37%): grade 1 in 3, grade 2 in 1, and grade 3 in
3; hepatic cytolysis in 2 (32%), both grade 1; and skin
rash in 2 (11%), both grade 1. However, all these patients
were receiving simultaneously multiple co-medications,
which may have been implicated in these AE. No AE
required discontinuation of caspofungin.
Discussion
Based on a previous study conducted in our institution,
we estimated that the risk of developing intra-abdominal
IC in patients with recurrent gastrointestinal perforations,
anastomotic leakages or acute necrotizing pancreatitis
ranges 30–40% [3]. In this study of preventive caspo-
fungin therapy in surgical patients enrolled on the basis of
a high-risk clinical profile before the colonization status
was known, this complication occurred in one single case
(5%). This failure occurred despite in vitro susceptibility
of the Candida isolates to caspofungin in a patient with a
severe unresolved surgical condition complicated by
intra-abdominal bleeding (primary cause of death) and
bacterial co-infection, in whom an IC at baseline could
not be ruled out. As expected from the drug safety profile,
no AE requiring discontinuation of caspofungin was
observed.
As in other studies in surgical patients with similar
high-risk profiles [3, 5, 8, 16, 17, 30], most patients were
colonized with Candida at baseline, but none with a CCI
exceeding 0.4, a previously reported powerful predictor of
Table 2 Candida colonization
At study entry At end of preventive
therapya
Patients colonized with Candida spp. 17/19 (89%) 9/14 (64%)b,c
Number of screened sites per patient, median (range) 4 (3–5) 4 (0–5)
Number of colonized sites per patient, median (range) 2 (0–4) 1.5 (0–3)
Number of sites colonized/number of sites screened 34/68 (50%) 17/53 (32%)d
Oropharynx 13/18 (72%) 5/12(42%)
Stools 7/7 (100%) 7/11 (64%)
Lower respiratory tract 7/9 (78%) 2/6 (33%)
Peritoneal fluid 6/17 (35%) 3/13 (23%)
Urine 1/17 (6%) 0/12 (0%)
Number of colonizing Candida isolates 39e 26e
Candida albicans 27/39 (69%) 19/26 (73%)
Non-albicans Candida species 12/39 (31%) 7/26 (27%)
a In patients who survived
b In 1 patient who was not colonized at baseline, colonization with
a non-albicans Candida species was documented at 1 site (stool)
during preventive therapy
c P = 0.11. In all patients, including those who died: 14/19 (74%)
d P = 0.06. In all patients, including those who died: 29/75 (39%)
e Four sites with C2 Candida species
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Fig. 1 Semi-quantitative assessment of the Candida colonization at
baseline and at end of preventive caspofungin therapy in patients
who survived. Panel a colonization index (CI = number of sites
colonized/number of sites screened). Panel b corrected coloniza-
tion index [CCI = (number of sites heavily colonized/number of
sites colonized) 9 colonization index]. Each symbol represents a
single patient. The horizontal bars represent the median values at
each time point. Previous studies have suggested that a CCI C0.4
may predict IC with a positive predictive value of 100%
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IC, which would have made them eligible for pre-emptive
antifungal therapy [8, 11]. The Candida colonization
index decreased at end of preventive therapy, and no
patient developed a CCI exceeding 0.4. This finding is
suggestive of a preventive action of caspofungin on the
development of a heavy colonization, one of the initial
steps in the pathogenesis of IC. No shift towards non-
albicans Candida species occurred during preventive
caspofungin therapy.
No experience is available on the efficacy of echino-
candins, a new class of fungicidal drugs active against
Candida species with decreased susceptibility to azoles,
for prevention of IC. Despite limitations such as the open
single-center non-comparative design and the small
sample size, the observations of this proof-of-concept
study suggest that caspofungin may be efficacious and
safe for prevention of intra-abdominal candidiasis in
surgical patients with a high-risk profile. This could be of
particular interest in hospitals with a high prevalence of
azole-resistant Candida species. The present exploratory
results provide a stepping stone to future randomized
studies designed to define the role of echinocandins for
prevention of IC in such a high-risk setting, and to assess
its impact on morbidity, mortality, and pharmaco-eco-
nomic issues. Whether other antifungals licensed for
therapy of IC, such as liposomal amphotericin B or vo-
riconazole, may also be efficacious for prevention of IC
needs to be investigated. Moreover, the utility of moni-
toring Candida colonization and of clinical prediction
rules for guiding the decision to start pre-emptive anti-
fungal therapy remains to be defined. Waiting for all these
additional data, fluconazole remains the recommended
first-line choice for a prevention based on straightforward
clinical criteria.
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